BRIEF-Cidara Therapeutics Announces Divestiture Of Rezafungin To Mundipharma

Reuters04-25

April 24 (Reuters) - Cidara Therapeutics Inc :

* CIDARA THERAPEUTICS ANNOUNCES DIVESTITURE OF REZAFUNGIN TO MUNDIPHARMA* TO FOCUS ON ADVANCING THE CLINICAL DEVELOPMENT OF CLOUDBREAK DFC PIPELINE

* CIDARA THERAPEUTICS INC - TRANSACTION PROVIDES COMPANY WITH AN ESTIMATED APPROXIMATELY $128 MILLION

* CIDARA THERAPEUTICS INC: TO FOCUS ON ADVANCING CLOUDBREAK DEVELOPMENT PROGRAMS, INCLUDING A PLANNED IND FILING FOR ITS LEAD ONCOLOGY CANDIDATE, CBO421

* CIDARA THERAPEUTICS INC - MUNDIPHARMA AGREED TO WAIVE CO'S OBLIGATION TO REIMBURSE MUNDIPHARMA FOR A $11.145 MILLION MILESTONE ADVANCE UNDER CONDITIONS

Source text for Eikon: Further company coverage:

(Reuters.Briefs@thomsonreuters.com)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2430498963?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-04-25 04:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2430498963","market":"us","top_or_hot":-1,"title":"BRIEF-Cidara Therapeutics Announces Divestiture Of Rezafungin To Mundipharma","media":"Reuters","content":"<html><body><p>April 24 (Reuters) - Cidara <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc   :</p><p>   * CIDARA THERAPEUTICS ANNOUNCES DIVESTITURE OF REZAFUNGIN TO MUNDIPHARMA* TO FOCUS ON ADVANCING THE CLINICAL DEVELOPMENT OF CLOUDBREAK DFC PIPELINE</p><p>   * CIDARA THERAPEUTICS INC - TRANSACTION PROVIDES COMPANY WITH AN ESTIMATED APPROXIMATELY $128 MILLION</p><p>   * CIDARA THERAPEUTICS INC: TO FOCUS ON ADVANCING CLOUDBREAK DEVELOPMENT PROGRAMS, INCLUDING A PLANNED IND FILING FOR ITS LEAD ONCOLOGY CANDIDATE, CBO421</p><p>   * CIDARA THERAPEUTICS INC - MUNDIPHARMA AGREED TO WAIVE CO'S OBLIGATION TO REIMBURSE MUNDIPHARMA FOR A $11.145 MILLION MILESTONE ADVANCE UNDER CONDITIONS</p><p>Source text for Eikon:    Further company coverage:   </p><p> (Reuters.Briefs@thomsonreuters.com)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Cidara Therapeutics Announces Divestiture Of Rezafungin To Mundipharma</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Cidara Therapeutics Announces Divestiture Of Rezafungin To Mundipharma\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-04-25 04:03 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>April 24 (Reuters) - Cidara Therapeutics Inc   :   * CIDARA THERAPEUTICS ANNOUNCES DIVESTITURE OF REZAFUNGIN TO MUNDIPHARMA* TO FOCUS ON ADVANCING THE CLINICAL DEVELOPMENT OF CLOUDBREAK DFC PIPELINE  ...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2430498963","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2430498963","pubTimestamp":1713988980,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"April 24  - Cidara Therapeutics Inc   :   * CIDARA THERAPEUTICS ANNOUNCES DIVESTITURE OF REZAFUNGIN TO MUNDIPHARMA* TO FOCUS ON ADVANCING THE CLINICAL DEVELOPMENT OF CLOUDBREAK DFC PIPELINE   * CIDARA THERAPEUTICS INC - TRANSACTION PROVIDES COMPANY WITH AN ESTIMATED APPROXIMATELY $128 MILLION   * CIDARA THERAPEUTICS INC: TO FOCUS ON ADVANCING CLOUDBREAK DEVELOPMENT PROGRAMS, INCLUDING A PLANNED IND FILING FOR ITS LEAD ONCOLOGY CANDIDATE, CBO421   * CIDARA THERAPEUTICS INC - MUNDIPHARMA AGREED TO WAIVE CO'S OBLIGATION TO REIMBURSE MUNDIPHARMA FOR A $11.145 MILLION MILESTONE ADVANCE UNDER CONDITIONSSource text for Eikon:    Further company coverage:    ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","CDTX":"Cidara Therapeutics, Inc."},"translate_title":"简介——Cidara Therapeutics宣布将瑞扎芬净剥离给Mundipharma","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CDTX":1},"content_text":"April 24 (Reuters) - Cidara Therapeutics Inc   :   * CIDARA THERAPEUTICS ANNOUNCES DIVESTITURE OF REZAFUNGIN TO MUNDIPHARMA* TO FOCUS ON ADVANCING THE CLINICAL DEVELOPMENT OF CLOUDBREAK DFC PIPELINE   * CIDARA THERAPEUTICS INC - TRANSACTION PROVIDES COMPANY WITH AN ESTIMATED APPROXIMATELY $128 MILLION   * CIDARA THERAPEUTICS INC: TO FOCUS ON ADVANCING CLOUDBREAK DEVELOPMENT PROGRAMS, INCLUDING A PLANNED IND FILING FOR ITS LEAD ONCOLOGY CANDIDATE, CBO421   * CIDARA THERAPEUTICS INC - MUNDIPHARMA AGREED TO WAIVE CO'S OBLIGATION TO REIMBURSE MUNDIPHARMA FOR A $11.145 MILLION MILESTONE ADVANCE UNDER CONDITIONSSource text for Eikon:    Further company coverage:    (Reuters.Briefs@thomsonreuters.com)","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2430498963"}